Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer

Taiwanese Journal of Obstetrics and Gynecology

Volumn 53, Issue 1, 2014, Pages 30-34

  Wu, Hua Hsi ^a   Wang, Peng Hui ^a,b,c   Yeh, Jiun Yih ^a   Chen, Yi Jen ^a   Yen, Ming Shyen ^a   Huang, Rui Lan ^d   Tsai, Yueh Ju ^d   Yuan, Chiou Chung ^d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cyfra 21 1; Cytokeratin 19 fragment; Epithelial ovarian cancer; Prognosis

Indexed keywords

CA 125 ANTIGEN; CYTOKERATIN 19 FRAGMENT; PLATINUM; ANTIGEN CYFRA21.1; ANTINEOPLASTIC AGENT; CYTOKERATIN 19; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; PLATINUM DERIVATIVE; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER RISK; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MIDDLE AGED; OVARY CARCINOMA; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; YOUNG ADULT; COMPARATIVE STUDY; DRUG RESISTANCE; KAPLAN MEIER METHOD; LYMPH NODE; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; RISK FACTOR; SECONDARY;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KERATIN-19; LYMPH NODES; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899126080     PISSN: 10284559     EISSN: 18756263     Source Type: Journal    
DOI: 10.1016/j.tjog.2013.02.002     Document Type: Article

References (42)

1. Siegel R., Desantis C., Virgo K., Stein K., Mariotto A., Smith T., et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62:220-241.
2. Shih C.Y., Lai C.R., Huang C.Y., Twu N.F., Chao K.C., Wang P.H. Achallenge in the management of a patient with ovarian cancer associated with extensive endometriosis. Taiwan J Obstet Gynecol 2012, 51:324-325.
3. Chao K.C., Wang P.H., Chang C.C., Yen M.S., Chi C.W. The role of estrogen in the survival of ovarian tumors-A study of the human ovarian adenocarcinoma cell lines OC117-VGH and OVCAR3. JChin Med Assoc 2013, 76:63-70.
4. Horng H.C., Wang P.H. Ovarian cancer presenting as an acute abdomen was successfully diagnosed and managed by laparoscopy. Taiwan J Obstet Gynecol 2012, 51:146-147.
5. Sun H.D., Tsai C.C., Hsiao S.M., Wei M.C., Wang K.C., Wang P.H. Primary gallbladder carcinoma presenting as advanced-stage ovarian cancer. Taiwan J Obstet Gynecol 2012, 51:443-445.
6. Su W.H., Ho T.Y., Li Y.T., Lu C.H., Lee W.L., Wang P.H. Metronomic therapy for gynecologic cancers. Taiwan J Obstet Gynecol 2012, 51:167-178.
7. Gupta D., Lis C.G. Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. JOvarian Res 2009, 2:13.
8. Kang W.D., Choi H.S., Kim S.M. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer. Gynecol Oncol 2010, 116:57-60.
9. Huang B.S., Seow K.M., Tsui K.H., Huang C.Y., Lu Y.F., Wang P.H. Fertility outcome of infertile women with adenomyosis treated with the combination of a conservative microsurgical technique and GnRH-agonist: long-term follow-up in a series of nine patients. Taiwan J Obstet Gynecol 2012, 51:212-216.
10. Sun H.D., Huang B.S., Chao H.T., Ng H.T., Wang P.H. Tuberculosis peritonitis. Taiwan J Obstet Gynecol 2012, 51:1-2.
11. Fang F.Y., Huang B.S., Chao H.T., Wang P.H. Ruptured ovarian endometrioma. Taiwan J Obstet Gynecol 2012, 51:145. [Comment].
12. Wang P.H., Liu W.M., Fuh J.L., Cheng M.H., Chao H.T. Comparison of surgery alone and combined surgical-medical treatment in the management of symptomatic uterine adenomyoma. Fertil Steril 2009, 92:876-885.
13. Gronlund B., Dehn H., Høgdall C.K., Engelholm S.A., Jorgensen M., Nørgaard- Pedersen B., et al. Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. Int J Gynecol Cancer 2005, 15:836-843.
14. Jacobs I., Bast R.C. The CA125 tumor associated antigen: a review of the literature. Hum Reprod 1989, 4:1-12.
15. Braicu E.I., Fotopoulou C., Van Gorp T., Richter R., Chekerov R., Hall C., et al. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol 2012, 128:245-251.
16. Nakata B., Ogawa Y., Ishikawa T., Ikeda K., Kato Y., Nishino H., et al. Serum CYFRA 21-1 I a one of the most reliable tumor marker for breast carcinoma. Cancer 2000, 89:1285-1290.
17. Nakata B., Takashima T., Ogawa Y., Ishikawa T., Hirakawa K. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumor marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer 2004, 91:873-878.
18. Uenishi T., Kubo S., Hirohashi K., Tanaka H., Shuto T., Yamamoto T., et al. Cytokeratin 19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer 2003, 88:1894-1899.
19. Pujol J.L., Molinier O., Ebert W., Daures J.P., Barlesi F., Buccheri G., et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of meta-analysis in 2063 patients. Br J Cancer 2004, 91:2097-2105.
20. Park S.Y., Lee J.G., Kim J., Park Y., Lee S.K., Bae M.K., et al. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung. Lung Cancer 2012, 79:156-160.
21. Giovanella L., Treglia G., Verburg F.A., Salvatori M., Geriani L. Serum cytokeratin 19 fragments: a dedifferentiation marker in advanced thyroid cancer. Eur J Endocrinol 2012, 167:793-797.
22. Jeong S., Park Y., Cho Y., Kim Y.R., Kim H.S. Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer. Clin Chim Acta 2012, 414:93-100.
23. Yan H.J., Wang R.B., Zhu K.L., Jiang S.M., Zhao W., Xu X.Q., et al. Cytokeratin 19 fragment antigen 21-1 as an independent predictor for definitive chemoradiotherapy sensitivity in esophageal squamous cell carcinoma. Chin Med J (Engl) 2012, 125:1410-1415.
24. Holdenrieder S., Stieber P., Liska V., Treska V., Topilcan O., Drelerova J., et al. Cytokeratin serum biomarkers in patients with colorectal cancer. Anticancer Res 2012, 32:1971-1976.
25. Zhu W.Q., Yu J.M., Sun X.D., Xie P., Kong L. Serum CYFRA21-1 as a prognostic marker for patients with undifferentiated nasopharyngeal carcinoma. Biomarkers 2010, 15:602-607.
26. Sheng X., Du X., Zhang X., Li D., Lu C., Li Q., et al. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat Med J 2009, 50:455-464.
27. Hasholzner U., Baumgartner L., Stieber P., Meier W., Hofmann K., Faten-Mohadam A. Significance of the tumor markers CA125 II, CA 72.4, ASA and CYFRA 21-1 in ovarian carcinoma. Anticancer Res 1994, 14:2743-2746.
28. Gadducci A., Ferdeghini M., Cosio S., Fanucchi A., Cristofani R., Genazzani A.R. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. Int J Gynecol Cancer 2001, 11:277-282.
29. Xenidis N., Ignatiadis M., Apostolaki S., Perraki M., Kalbakis K., Agelaki S., et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. JClin Oncol 2009, 27:2177-2184.
30. Tempfer C., Hefler L., Heinzl H., Loesch A., Gitsch G., Rumpold H., et al. CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases. Br J Cancer 1998, 78:1108-1112.
31. Yuan C.C., Tsai L.C., Hsu S.C. Production and characterization of a monoclonal antibody (Cx-99) against cervical carcinoma. Br J Cancer 1992, 65:201-207.
32. Dohmoto K., Hojo S., Fujita J., Yang Y., Ueda Y., Bandoh S., et al. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. Int J Cancer 2001, 91:468-473.
33. Gmyr V., Kerr-Conte J., Belaich S., Vandewalle B., Leteurtre E., Vantyghem M.C., et al. Adult human cytokeratin 19-positive cells reexpress insulin promoter factor 1 invitro: further evidence for pluripotent pancreatic stem cells in humans. Diabetes 2000, 49:1671-1680.
34. Gudjonsson T., Villadsen R., Nielsen H.L., Rønnov-Jessen L., Bissell M.J., Petersen O.W. Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev 2002, 16:693-706.
35. Lennerz J.K., Chapman W.C., Brunt E.M. Keratin 19 epithelial patterns in cirrhotic stroma parallel hepatocarcinogenesis. Am J Pathol 2011, 179:1015-1029.
36. Paraio J.M., Jorcano J.L. Beyond structure: do intermediate filaments modulate cell signaling?. BioEssays 2002, 24:836-844.
37. Bodenmüller H., Ofenloch-Hahnle B., Lane E.B., Dessauer A., Böttger V., Donie F. Lung cancer-associated keratin 19 fragments: development and biochemical characterization of the new serum assay enzymum-test CYFRA 21-1. Int J Biol Markers 1994, 9:75-81.
38. Moll R., Franke W.W., Schiller D.L., Geiger B., Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982, 31:11-24.
39. Einhorn N., Sjövall K., Knapp R.C., Hall P., Scully R.E., Bast R.C., et al. Prospective evaluation of serum CA125 levels for early detection of ovarian cancer. Obstet Gynecol 1993, 80:14-18.
40. Gershenson D.M., Kavanagh J.J., Copeland L.J., Stringer C.A., Morris M., Wharton J.T. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet Gynecol 1989, 73:798-802.
41. Yuan C.C., Huang H.C., Tsai L.C., Ng H.T., Huang T.S. Cytokeratin-19 associated with apoptosis and chemosensitivity in human cervical cancer cells. Apoptosis 1997, 2:101-105.
42. Parekh H.K., Simpkins H. The differential expression of cytokeratin 18 in cisplatin-sensitive and -resistant human ovarian adenocarcinoma cells and its association with drug sensitivity. Cancer Res 1995, 55:5203-5206.